Y
Ying Cheng
Researcher at National Taiwan University
Publications - 106
Citations - 2067
Ying Cheng is an academic researcher from National Taiwan University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 12, co-authored 56 publications receiving 1376 citations.
Papers
More filters
Journal ArticleDOI
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Jin Li,Shukui Qin,Jianming Xu,Jianping Xiong,Changping Wu,Yuxian Bai,Wei Liu,Jiandong Tong,Yunpeng Liu,Rui-Hua Xu,Zhehai Wang,Qiong Wang,Xuenong Ouyang,Yan Yang,Yi Ba,Jun Liang,Xiaoyan Lin,Deyun Luo,Rongsheng Zheng,Xin Wang,Guoping Sun,Liwei Wang,Leizhen Zheng,Hong Guo,Jingbo Wu,Nong Xu,Jianwei Yang,Hong-gang Zhang,Ying Cheng,Ningju Wang,Lei Chen,Zhining Fan,Piaoyang Sun,Hao Yu +33 more
TL;DR: These data show that apatinib treatment significantly improved OS and PFS with an acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy.
Journal ArticleDOI
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
Calin Cainap,Shukui Qin,Wen-Tsung Huang,Ik Joo Chung,Hongming Pan,Ying Cheng,Masatoshi Kudo,Yoon-Koo Kang,Pei-Jer Chen,Han Chong Toh,Vera Gorbunova,Ferry A.L.M. Eskens,Jiang Qian,Mark D. McKee,Justin L. Ricker,Dawn M. Carlson,Saied El-Nowiem +16 more
TL;DR: Linifanib and sorafenib had similar OS in advanced HCC and the study failed to meet the primary end point, despite defined superiority and noninferiority OS boundaries being met.
Journal ArticleDOI
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
Wen-Zhao Zhong,Qun Wang,Weimin Mao,Songtao Xu,Lin Wu,Yucheng Wei,Yongyu Liu,Chun Chen,Ying Cheng,Rong Yin,Fan Yang,Shengxiang Ren,Xiaofei Li,Jian Li,Cheng Huang,Zhidong Liu,Shun Xu,Ke-Neng Chen,Shidong Xu,Lunxu Liu,Ping Yu,Bu-Hai Wang,Haitao Ma,Jin-Ji Yang,Hong-Hong Yan,Xue-Ning Yang,Si-Yang Liu,Qing Zhou,Yi-Long Wu +28 more
TL;DR: Adjuvant therapy with gefitinib in patients with early-stage NSCLC and EGFR mutation demonstrated improved DFS over standard of care chemotherapy, which was one of the longest observed in this patient group compared with historic data.
Journal ArticleDOI
Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC).
Calin Cainap,Shukui Qin,Wen-Tsung Huang,Ik-Joo Chung,Hongming Pan,Ying Cheng,Masatoshi Kudo,Yoon-Koo Kang,Pei-Jer Chen,Han Chong Toh,Vera Gorbunova,Ferry A.L.M. Eskens,Jiang Qian,Mark D. McKee,Justin L. Ricker,Dawn M. Carlson,Saied El Nowiem +16 more
TL;DR: This open-label, global phase 3 trial evaluated Lin versus sorafenib (Sor) as first-line therapy in pts with advanced CPA HCC and overall survival was overall survival (OS).
Journal ArticleDOI
Efficacy of Aumolertinib (HS-10296) in Patients with Advanced EGFR T790M+ NSCLC: Updated Post NMPA-approval Results from the APOLLO Registrational Trial
SILVA J.S,Shun Lu,Qiming Wang,Guojun Zhang,Xiaorong Dong,Cheng-Ta Yang,Yong Song,Gee-Chen Chang,You Lu,Hongming Pan,Chao-Hua Chiu,Zhehai Wang,Jifeng Feng,Jianying Zhou,Xingxiang Xu,R. Guo,Jianhua Chen,Haihua Yang,Yuan Chen,Zhuang Yu,Her-Shyong Shiah,Chin-Chou Wang,Nong Yang,Jian Fang,Ping Wang,Kai Wang,Yanping Hu,Jianxing He,Ziping Wang,Jianhua Shi,Shaoshui Chen,Qiong Wu,Changan Sun,Chuan Li,Hongying Wei,Ying Cheng,Wu Chou Su,Te Chun Hsia,Jiuwei Cui,Yuping Sun,Sai-Hong Ignatius Ou,Viola W. Zhu,James Chih-Hsin Yang +42 more
TL;DR: Aumolertinib as discussed by the authors is a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with demonstrated activity against EGFR sensitizing mutations and EGFR T790M mutation.